NEW INITIATIVE TAKES ON THE ANTIBIOTIC INNOVATION CHALLENGE

Acting now – public and private sector – shared goal to develop a robust pipeline of effective new antibiotics to safeguard our future.

The world is losing its most powerful tool in healthcare: antibiotics. The reason is rapidly rising antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The world needs new antibiotics to stem the toll superbugs are having on patients, but there are few in the pipeline. This is the result of a long-standing paradox: despite the huge societal costs of AMR, there is currently no viable market for new antibiotics. In the long run, the uncontrolled rise of AMR could have public health and economic consequences greater than COVID-19. But unlike COVID-19, AMR is a predictable and preventable crisis – we must take action now.

PRESS CONFERENCE - 14:30 to 15:10 CEST

Hubertus von Baumbach, Chairman of the Board of Managing Directors, Boehringer Ingelheim
Kasim Kutay, CEO, Novo Holdings
Stefan Oelrich, CEO Bayer Pharmaceuticals
Stefan Oschmann, Chairman of the Executive Board and CEO of Merck
As well as pharmaceutical industry federation representatives: Thomas Cueni, Director-General, IFPMA, Nathalie Moll, Director General, EFPIA

LAUNCH EVENT - 3:15-5:00 PM CEST:

Introducing the new initiative - Bridging the gap between science and patients

- The problem, complication, and solution: Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

- The pharmaceutical industry investors:

Hubertus von Baumbach, Chairman of the Board of Managing Directors, Boehringer Ingelheim
Messages from: Emma Walmsley CEO GSK, Deborah Dunsire, President & CEO Lundbeck, Vas Narasimhan, CEO Novartis, Severin Schwan CEO Roche Group, Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson

The AMR public health challenge: Dame Sally Davies, UK Special Envoy on antimicrobial resistance (AMR)

Public health response to the initiative

Dr Tedros Adhanom Ghebreyesus, Director General, World Health Organization
Werner Hoyer, President, European Investment Bank
Jeremy Farrar, Director, Wellcome Trust

PANEL: The inventor, investment and partnerships to bridge the gap

Tiemo Wölken, MEP S&D German, vice-chair of European Parliament MEP Interest Group on AMR
Florence Séjourné, CEO, Da Volterra and President BEAM Alliance
Kasim Kutay, CEO, Novo Holdings
Stefan Oelrich, CEO Bayer Pharmaceuticals

PANEL: The world urgently needs new antibiotics – politics, leadership and public health

Health Ministers and the need for antibiotics innovation to tackle AMR

Jens Spahn, Federal Minister of Health, Germany
Magnus Heunicke, Minister of Health and Senior Citizens, Denmark

Joined by

Agnès Pannier-Runacher, Minister of Industry, France
Stella Kyriakides, European Commissioner for Health and Food Safety
Stefan Oschmann, Chairman of the Executive Board and CEO of Merck
Nathalie Moll, Director General, EFPIA

What’s in a name: launching the new initiative - Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

Following registration, details on how to join the webstream will be sent by email. During the virtual event, participants will be able to put questions in writing to the speakers.

Please feel free to share this link with other colleagues.

The AMR initiative global launch events will take place in Berlin and Washington, D.C. simultaneously on July 9, with an event in Tokyo to follow on July 10 2020. Use this link for more information about the global launch and to sign up to these events.

Organized by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) with the support of EFPIA and Vfa.

BERLIN EVENT – A NEW INITIATIVE TAKES ON THE ANTIBIOTIC CHALLENGE